PCSK9 and familial hyperaldosteronism: Lowering of Lp(a) with PCSK9 inhibitors has been shown to contribute to a reduction in ASCVD events in post-ACS and high-risk patients (Bittner et al., 2020; O'Donoghue et al., 2019), but trials have not been undertaken specifically in patients with FH.